论文部分内容阅读
目的:以群体药物动力学原理分析复方冠心Ⅱ不同组成条件对主要组分芍药苷及阿魏酸体内过程的影响.方法:将大鼠随机分组后分别静脉注射芍药苷(PPE)或阿魏酸(FA)提取物水溶液、灌胃给予PPE或FA水溶液及不同组成的水煎液,HPLC法测定血浆中芍药苷和阿魏酸浓度,以非线性混合效应模型(NONMEM)法分别对芍药苷和阿魏酸的血药浓度数据进行群体药物动力学解析.结果:芍药苷的体内药物动力学过程可用吸收相包含一级降解过程的二室口服吸收模型进行表述,参数CL1、V1、CL2、V2、Ka0和Ka1分别为 0.509 L/h, 0.104 L, 0.113 L/h, 0.123 L, 0.135 /h及 0.0135 /h;阿魏酸的体内过程可用二室口服吸收模型表述,参数CL1、V1、CL2、V2,、Ka及F分别为 0.295 L/h、0.025 L、0.0331 L/h、0.0518 L、0.110 /h 及 0.40.模型化中对个体间差异进行了估计,并以给药组方因素(DF)作为固定效应对参数进行了校正.结论:群体药物动力学方法可以用于分析中药复方冠心Ⅱ中组方变化对其中指标成分的体内吸收和分布产生的影响,较以往的方法有一定的优越性.“,”To evaluate the effect of components in Guanxin Ⅱ prescription on the pharmacokinetic profiles of paeoniflorin and ferulic acid. METHODS: Drug concentrations of rat plasmas after intravenous injection of paronia pall (PPE) or ferulic acid (FA) extract solution, as well as oral administration of PPE and FA solution, and different kinds of decoctions based on Guanxin Ⅱ prescription were determined by an HPLC system. NONMEM (nonlinear mixed-effect modeling) method was used to analyze the population pharmacokinetics of PF and FA. RESULTS: A two-compartment model with first order degradation in absorption phase, and an ordinary two-compartment model were adequately describe PF and FA pharmacokinetic profiles, respectively. The mean of PF population parameters, CL1, V1, CL2, V2, Ka0, and Ka1, were 0.509 L/h, 0.104 L, 0.113 L/h, 0.123 L, 0.135 /h, and 0.0135 /h, respectively, while the typical values of CL1, V1, CL2, V2, Ka1, and F in FA model were 0.295 L/h, 0.025 L, 0.0331 L/h, 0.0518 L, 0.110 /h, and 0.40, respectively. Inter-individual variabilities were estimated and dose formulation (DF) was identified as a significant covariate in the model. CONCLUSION: The results indicate that the pharmacokinetic behaviors of index components in Guanxin Ⅱ prescription can be influenced by different dose formulations administrated in rats.